ReviewJournal of advanced research2013
Urinary schistosomiasis: review.
Review in Journal of advanced research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 113 citations in OpenAlex.
- Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt.The American journal of tropical medicine and hygiene · 2014Trial
- Urinary schistosomiasis in a patient from an endemic region.Urology case reports · 2026Article
- Case report: Radiographic and cystoscopic manifestations of chronic urogenital Schistosomiasis in an asymptomatic Zimbabwean man with HIV.Urology case reports · 2026Article
- Article
- Distribution of schistosomes and soil-transmitted helminth infections and their association with growth and nutritional status of School-aged children of the Matta health area in the West region of Cameroon.PLoS neglected tropical diseases · 2025Article
- Therapeutic challenges of schistosomiasis: mechanisms of action and current limitations.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Review
- From dysbiosis to precision therapy: decoding the gut-bladder axis in bladder carcinogenesis.Frontiers in oncology · 2025Review
- The infection-microbiome-immunity axis in bladder cancer: mechanistic insights and therapeutic perspectives.Frontiers in immunology · 2025Review
- RNA-seq gene expression profiling of the bladder in a mouse model of urogenital schistosomiasis.bioRxiv : the preprint server for biology · 2024Article
- Trematode Genomics and Proteomics.Advances in experimental medicine and biology · 2024Article
- A unique case ofIJU case reports · 2023Article
- Review
- Schistosomal (bilharzial) polyps: Travel through the colon and beyond.World journal of gastroenterology · 2023Review
- The trend of schistosomiasis related bladder cancer in the lake zone, Tanzania: a retrospective review over 10 years period.Infectious agents and cancer · 2023Review
- Forgotten but not gone in rural South Africa: Urinary schistosomiasis and implications for chronic kidney disease screening in endemic countries.Wellcome open research · 2023Article
- Toward schistosomiasis control: Assessment of infection-associated voiding symptoms, quality of life and the impact of exercise coupled with water intake on egg recovery in an endemic community in Ghana.PLOS global public health · 2023Article
- Kidney complications of parasitic diseases.Nature reviews. Nephrology · 2022Review
- Urinary schistosomiasis: a case of late presentation.BMJ case reports · 2022Article
- Prevalence of urinary schistosomiasis in women: a systematic review and meta-analysis of recently published literature (2016-2020).Tropical medicine and health · 2022Review
- The parasitology of female genital schistosomiasis.Current research in parasitology & vector-borne diseases · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledIn this review, the clinical manifestations of urinary schistosomiasis are displayed from a pathogenetic perspective. According to the prevailing host's immune response profile, urinary schistosomiasis may be broadly categorized into cell-mediated and immune-complex-mediated disorders. The former, usually due to Schistosoma haematobium infection, are attributed to the formation of granulomata along the entire urinary tract. As they heal with excessive fibrosis, they may lead to strictures, calcifications and urodynamic abnormalities. The main impact is lower urinary, the site of heaviest ovi-position. Secondary bacterial or viral infection is common, any may be incriminated in secondary stone formation of the development of bladder malignancy. Immune-complex mediated lesions are usually associated with hepatosplenic schistosomiasis due to Schistosoma mansoni infection. Circulating complexes composed of schistosomal gut antigens and different classes of immunoglobulins deposit in the kidneys leading to several patterns of glomerular pathology. The latter have been categorized under six classes based on the histological and immunofluorescence profile. These classes have been linked to respective clinical manifestations and depend on the stage of evolution of the host's immune response, extent of associated hepatic fibrosis and co-infection with salmonella or hepatitis C. Secondary amyloidosis develops in 15% of such patients, representing a critical impairment of macrophage function.
conclusionThe wide clinicopathological spectrum of urinary schistosomiasis mirrors the evolution of the host's immune response according to chronicity of infection, bacterial or viral co-infection and, in the case of glomerulonephritis, to the extent of hepatic co-morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.